Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal Sabine E. GrimmDebra FayterManuela A. Joore Review Article Open access 21 March 2019 Pages: 1195 - 1207
Tisagenlecleucel for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia in People Aged up to 25 Years: An Evidence Review Group Perspective of a NICE Single Technology Appraisal Matthew WaltonSahar SharifRobert Hodgson Review Article 13 April 2019 Pages: 1209 - 1217
Structural Design and Data Requirements for Simulation Modelling in HIV/AIDS: A Narrative Review Xiao ZangEmanuel Krebsthe Localized HIV modeling study group Review Article 21 June 2019 Pages: 1219 - 1239
Cost Effectiveness of Advanced Pharmacy Services Provided in the Community and Primary Care Settings: A Systematic Review Dalia M. DawoudAlexander HainesJulian Bion Systematic Review 10 June 2019 Pages: 1241 - 1260
Decision Models for Assessing the Cost Effectiveness of Treatments for Pediatric Drug-Resistant Epilepsy: A Systematic Review of Economic Evaluations Jesse ElliottSasha van KatwykDoug Coyle Systematic Review 14 June 2019 Pages: 1261 - 1276
Cost-Effectiveness Analysis of Non-Statin Lipid-Modifying Agents for Secondary Cardiovascular Disease Prevention Among Statin-Treated Patients in Thailand Khachen KongpakwattanaZanfina AdemiNathorn Chaiyakunapruk Original Research Article 26 June 2019 Pages: 1277 - 1286
Adoption of Cost Effectiveness-Driven Value-Based Formularies in Private Health Insurance from 2010 to 2013 Elizabeth D. BrouwerAnirban BasuKai Yeung Original Research Article 04 July 2019 Pages: 1287 - 1300
Comment on: ‘The Impact of Hospital Costing Methods on Cost-Effectiveness Analysis: A Case Study’ Livio GarattiniAnna Padula Letter to the Editor 27 June 2019 Pages: 1301 - 1302
